MAUNA KEA TECHNOLOGIES (EPA:MKEA) MAUNA KEA TECHNOLOGIES AND THE AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY PARTNER IN ORDER TO ADVANCE PATIENT CARE AND DIGESTIVE HEALTH BY PROMOTING EXCELLENCE AND INNOVATION IN ENDOSCOPY

Transparency directive : regulatory news

27/09/2011 17:45

Press release

MAUNA KEA TECHNOLOGIES AND THE AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY
   PARTNER IN ORDER TO ADVANCE PATIENT CARE AND DIGESTIVE HEALTH BY PROMOTING
                     EXCELLENCE AND INNOVATION IN ENDOSCOPY

       Mauna Kea Technologies provides grant to support ASGE initiatives

PARIS (September 27, 2011) - Mauna Kea Technologies (NYSE Euronext: MKEA),
leader in the endomicroscopy market, today announced a corporate partnership
with the American Society for Gastrointestinal Endoscopy (ASGE). The
collaboration demonstrates Mauna Kea Technologies' commitment to help the ASGE
achieve its mission to advance patent care and digestive health by promoting
excellence and innovation in endoscopy.

"Support from corporate partners such as Mauna Kea Technologies helps us expand
the understanding and practical application of medical innovations that improve
our ability to diagnose and treat patents," said ASGE President Gregory G.
Ginsberg, MD, FASGE. "We look forward to working together with Mauna Kea as a
long-term partner to deliver on our society's goal of improving GI health."

The ASGE advances patent care by supporting research and moving it quickly into
practice; keeping practitioners on the cutting edge through specialized
education and training; and raising awareness and understanding of GL
endoscopy-related health issues through public outreach initiatives. The ASGE
also helps patents  find qualified endoscopists.

"Mauna Kea Technologies is dedicated to working closely with ASGE to support
education, training and adoption of innovative technologies including
Cellvizio(r)," said Sacha Loiseau, founder and CEO, Mauna Kea Technologies. "We
have dedicated ourselves to developing and rigorously evaluating advanced
endoscopy tools that provide physicians with more real-time visual information
than they've ever had before. We are proud to be a corporate partner with the
ASGE due to its tireless efforts to move the field of endoscopy forward. We
also applaud the ASGE's efforts to offer gastroenterologists access to training
with the latest technologies that have the potential to change the way GL
disease is detected and treated. We look forward to a long-term relationship
with the society."

About the ASGE Foundation GI Corporate Partners Program
The ASGE Foundation is the philanthropic arm of the American Society for
Gastrointestinal Endoscopy. Its mission is to provide long-term financial
support for ASGE by raising funds and building endowments through charitable
gifts and contributions. Through unrestricted contributions to the ASGE
Foundation, GL Corporate Partners demonstrate their shared commitment to
partner in ASGE's mission to advance patent care and digestive health by
promoting excellence and innovation in endoscopy.

About the American Society for Gastrointestinal Endoscopy
Since its founding in 1941, the American Society for Gastrointestinal Endoscopy
(ASGE) has been dedicated to advancing patent care and digestive health by
promoting excellence in gastrointestinal endoscopy. ASGE, with nearly 12,000
members worldwide, promotes the highest standards for endoscopic training and
practice, fosters endoscopic research, recognizes distinguished contributions
to endoscopy, and is the foremost resource for endoscopic education. Visit
www.asge.org and www.screen4coloncancer.org for more information and to find a
qualified doctor in your area.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the
endomicroscopy market. The company researches, develops and markets innovative
tools to visualize and detect abnormalities in the gastro-intestinal and
pulmonary tracts. Its flagship product, Cellvizio(r), a probe-based Confocal
Laser Endomicroscopy (pCLE) system, provides physicians and researchers
high-resolution cellular views of tissue inside the body. Large, international,
multi-center clinical trials have demonstrated Cellvizio's ability to help
physicians more accurately detect early forms of disease and make treatment
decisions immediately. Designed to improve patent outcomes and reduce costs
within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio
has 510(k) clearance from the U.S. Food and Drug Administration and the
European CE-Mark for use in the GL and pulmonary tracts.

For more information about Mauna Kea Technologies visit www.maunakeatech.com

Disclaimer
This press release and the information contained herein do not constitute an
offer to sell or subscribe to, or a solicitation of an offer to buy or
subscribe to, shares in Mauna Kea Technologies ("the Company") in any country.
This press release contains forward-looking statements that relate to the
Company's objectives. Such forward-looking statements are based solely on the
current expectations and assumptions of the Company's management and involve
risk and uncertainties. Potential risks and uncertainties include, without
limitation,
whether the Company will be successful in implementing its strategies, whether
there will be continued growth in the relevant market and demand for the
Company's products, new products or technological developments introduced by
competitors, and risks associated with managing growth. Unfavorable
developments in connection with these and other risks and uncertainties
described, in particular, in the Company's prospectus prepared in connection
with its IPO and on which the French Autorité des marches financiers ("AMF")
granted its visa number 11-236 on June 230, 2011, could cause the Company to
fail to achieve the objectives expressed by the forward-looking statements
above.

United States                          France and Europe
Erich Sandoval                         ALIZE RP
Lazar Partners Ltd.                    Caroline Carmagnol
+1 917 497 2867                        + 33 1 42 68 86 43 // + 33 6 64 18 99 59
esandoval@lazarpartners.com            caroline@alizerp.com
                                       Anne-Sophie Cosquéric
Mauna Kea Technologies                 + 33 1 42 68 86 41
Alexander Bryson                       Anne-sophie@alizerp.com
Marketing Communications
and Brand Manager
Tel: +33 (0) 1 70 08 09 92
alexander@maunakeatech.com

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) MAUNA KEA TECHNOLOGIES AND THE AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY PARTNER IN ORDER TO ADVANCE PATIENT CARE AND DIGESTIVE HEALTH BY PROMOTING EXCELLENCE AND INNOVATION IN ENDOSCOPY

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories